Mabrouk N, Racoeur C, Shan J, Massot A, Ghione S, Privat M, Dondaine L, Ballot E, Truntzer C, Boidot R, Hermetet F, Derangère V, Bruchard M, Végran F, Chouchane L, Ghiringhelli F, Bettaieb A, Paul C

Cancers (Basel). 2023 06 9;15(12):

Editorial: Targeting glucose metabolism in cancer immunity and immunotherapy.

Feron O, Chang CH, Végran F

Front Immunol. 2023 03 8;14:1171274

Canonical and non-canonical functions of NLRP3.

Accogli T, Hibos C, Vegran F

J Adv Res. 2023 01 4;:

Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects.

Mary R, Chalmin F, Accogli T, Bruchard M, Hibos C, Melin J, Truntzer C, Limagne E, Derangère V, Thibaudin M, Humblin E, Boidot R, Chevrier S, Arnould L, Richard C, Klopfenstein Q, Bernard A, Urade Y, Harker JA, Apetoh L, Ghiringhelli F, Végran F

Cancer Immunol Res. 2022 05 25;:OF1-OF17

NLRP6 negatively regulates type 2 immune responses in mice.

Chenuet P, Marquant Q, Fauconnier L, Youness A, Mellier M, Marchiol T, Rouxel N, Messaoud-Nacer Y, Maillet I, Ledru A, Quesniaux VFJ, Ryffel B, Horsnell W, Végran F, Apetoh L, Togbe D

Allergy. 2022 05 25;:

Role of Cytokines and Chemokines in Angiogenesis in a Tumor Context.

Geindreau M, Bruchard M, Vegran F

Cancers (Basel). 2022 05 16;14(10):

Protein Kinase Inhibitor-Mediated Immunoprophylactic and Immunotherapeutic Control of Colon Cancer.

Ghione S, Racoeur C, Mabrouk N, Shan J, Groetz E, Ballot E, Truntzer C, Chouchane L, Végran F, Paul C, Plenchette S, Bettaieb A

Front Immunol. 2022 04 28;13:875764

Impact of Lipid Metabolism on Antitumor Immune Response.

Mabrouk N, Lecoeur B, Bettaieb A, Paul C, Végran F

Cancers (Basel). 2022 Apr 6;14(7):

Alternative Splicing in Cancer and Immune Cells.

Bernard A, Boidot R, Végran F

Cancers (Basel). 2022 Mar 28;14(7):

Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses.

Bruchard M, Geindreau M, Perrichet A, Truntzer C, Ballot E, Boidot R, Racoeur C, Barsac E, Chalmin F, Hibos C, Baranek T, Paget C, Ryffel B, Rébé C, Paul C, Végran F, Ghiringhelli F

Nat Immunol. 2022 Feb;23(2):262-274

CD4 T cell-intrinsic STING signaling controls the differentiation and effector functions of T1 and T9 cells.

Benoit-Lizon I, Jacquin E, Rivera Vargas T, Richard C, Roussey A, Dal Zuffo L, Martin T, Melis A, Vinokurova D, Shahoei SH, Baeza Garcia A, Pignol C, Giorgiutti S, Carapito R, Boidot R, Végran F, Flavell RA, Ryffel B, Nelson ER, Soulas-Sprauel P, Lawrence T, Apetoh L

J Immunother Cancer. 2022 01;10(1):

Follicular helper-T cells restore CD8-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy.

Niogret J, Berger H, Rebe C, Mary R, Ballot E, Truntzer C, Thibaudin M, Derangère V, Hibos C, Hampe L, Rageot D, Accogli T, Joubert P, Routy B, Harker J, Vegran F, Ghiringhelli F, Chalmin F

J Immunother Cancer. 2021 Jun;9(6):

Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment.

Accogli T, Bruchard M, Végran F

Cancers (Basel). 2021 Jan 20;13(3):

The tumor microenvironment impairs Th1 IFNγ secretion through alternative splicing modifications of Irf1 pre-mRNA.

Bernard A, Hibos C, Richard C, Viltard E, Chevrier S, Lemoine S, Melin J, Humblin E, Mary R, Accogli T, Chalmin F, Bruchard M, Peixoto P, Hervouet E, Apetoh L, Ghiringhelli F, Vegran F, Boidot R

Cancer Immunol Res. 2021 Jan 8;:

Cleaved Caspase-3 transcriptionally regulates angiogenesis promoting chemotherapy resistance.

Bernard A, Chevrier S, Beltjens F, Dosset M, Viltard E, Lagrange A, Dérangère V, Oudot A, Ghiringhelli F, Collin B, Apetoh L, Feron O, Chen S, Arnould L, Végran F, Boidot R

Cancer Res.. 2019 Oct 14;:

Regulation of T cell antitumor immune response by tumor induced metabolic stress.

Chalmin F, Bruchard M, Vegran F, Ghiringhelli F

Cell Stress. 2018 Nov 27;3(1):9-18

PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer.

Dosset M, Vargas TR, Lagrange A, Boidot R, Végran F, Roussey A, Chalmin F, Dondaine L, Paul C, Marie-Joseph EL, Martin F, Ryffel B, Borg C, Adotévi O, Ghiringhelli F, Apetoh L

Oncoimmunology. 2018 ;7(6):e1433981

Transcriptional Programs Underlying Cd4 T Cell Differentiation and Functions.

Chalmin F, Humblin E, Ghiringhelli F, Végran F

Int Rev Cell Mol Biol. 2018 ;341:1-61

IRF8-dependent molecular complexes control the Th9 transcriptional program.

Humblin E, Thibaudin M, Chalmin F, Derangère V, Limagne E, Richard C, Flavell RA, Chevrier S, Ladoire S, Berger H, Boidot R, Apetoh L, Végran F, Ghiringhelli F

Nat Commun. 2017 Dec 12;8(1):2085

Sirtuin-1 Activation Controls Tumor Growth by Impeding Th17 Differentiation via STAT3 Deacetylation.

Limagne E, Thibaudin M, Euvrard R, Berger H, Chalons P, Végan F, Humblin E, Boidot R, Rébé C, Derangère V, Ladoire S, Apetoh L, Delmas D, Ghiringhelli F

Cell Rep. 2017 Apr;19(4):746-759

TH9 cells in anti-tumor immunity.

Rivera Vargas T, Humblin E, Végran F, Ghiringhelli F, Apetoh L

Semin Immunopathol. 2017 Jan;39(1):39-46

The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?

Eliade M, Skrzypski J, Baurand A, Jacquot C, Bertolone G, Loustalot C, Coutant C, Guy F, Fumoleau P, Duffourd Y, Arnould L, Delignette A, Padéano MM, Lepage C, Raichon-Patru G, Boudrant A, Bône-Lépinoy MC, Villing AL, Charpin A, Peignaux K, Chevrier S, Vegran F, Ghiringhelli F, Boidot R, Sevenet N, Lizard S, Faivre L

Oncotarget. 2017 Jan;8(2):1957-1971

Transcription Factor Binding Studies in CD4+ T Cells: siRNA Transfection, Chromatin Immunoprecipitation, and Liquid Luminescent DNA Precipitation Assay.

Humblin E, Ghiringhelli F, Végran F

Methods Mol. Biol.. 2017 ;1585:167-177

Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein.

Ghiringhelli F, Richard C, Chevrier S, Végran F, Boidot R

World J. Gastroenterol.. 2016 Dec;22(48):10680-10686

Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen.

Limagne E, Euvrard R, Thibaudin M, Rébé C, Derangère V, Chevriaux A, Boidot R, Végran F, Bonnefoy N, Vincent J, Bengrine-Lefevre L, Ladoire S, Delmas D, Apetoh L, Ghiringhelli F

Cancer Res.. 2016 Sep;76(18):5241-52

[Th9 cells: a new population of helper T cells].

Vegran F, Martin F, Apetoh L, Ghiringhelli F

Med Sci (Paris). 2016 Apr;32(4):387-93

Transcriptome analysis of TH2 CD4(+) T cells differentiated from wild-type and NLRP3KO mice.

Bruchard M, Boidot R, Ghiringhelli F, Vegran F

Genom Data. 2015 Jul 9;5:314-5

The receptor NLRP3 is a transcriptional regulator of TH2 differentiation.

Bruchard M, Rebe C, Derangere V, Togbe D, Ryffel B, Boidot R, Humblin E, Hamman A, Chalmin F, Berger H, Chevriaux A, Limagne E, Apetoh L, Vegran F, Ghiringhelli F

Nat Immunol. 2015 Aug;16(8):859-70

Liver X receptor beta activation induces pyroptosis of human and murine colon cancer cells.

Derangere V, Chevriaux A, Courtaut F, Bruchard M, Berger H, Chalmin F, Causse SZ, Limagne E, Vegran F, Ladoire S, Simon B, Boireau W, Hichami A, Apetoh L, Mignot G, Ghiringhelli F, Rebe C

Cell Death Differ. 2014 Dec;21(12):1914-24

The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells.

Vegran F, Berger H, Boidot R, Mignot G, Bruchard M, Dosset M, Chalmin F, Rebe C, Derangere V, Ryffel B, Kato M, Prevost-Blondel A, Ghiringhelli F, Apetoh L

Nat Immunol. 2014 Aug;15(8):758-66

Survivin-3B potentiates immune escape in cancer but also inhibits the toxicity of cancer chemotherapy.

Vegran F, Mary R, Gibeaud A, Mirjolet C, Collin B, Oudot A, Charon-Barra C, Arnould L, Lizard-Nacol S, Boidot R

Cancer Res. 2013 Sep 1;73(17):5391-401

SOCS3 transactivation by PPARgamma prevents IL-17-driven cancer growth.

Berger H, Vegran F, Chikh M, Gilardi F, Ladoire S, Bugaut H, Mignot G, Chalmin F, Bruchard M, Derangere V, Chevriaux A, Rebe C, Ryffel B, Pot C, Hichami A, Desvergne B, Ghiringhelli F, Apetoh L

Cancer Res. 2013 Jun 15;73(12):3578-90

Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.

Hervieu A, Rébé C, Végran F, Chalmin F, Bruchard M, Vabres P, Apetoh L, Ghiringhelli F, Mignot G

J. Invest. Dermatol.. 2013 Feb;133(2):499-508

Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells.

Bugaut H, Bruchard M, Berger H, Derangère V, Odoul L, Euvrard R, Ladoire S, Chalmin F, Végran F, Rébé C, Apetoh L, Ghiringhelli F, Mignot G

PLoS ONE. 2013 ;8(6):e65181

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.

Bruchard M, Mignot G, Derangère V, Chalmin F, Chevriaux A, Végran F, Boireau W, Simon B, Ryffel B, Connat JL, Kanellopoulos J, Martin F, Rébé C, Apetoh L, Ghiringhelli F

Nat. Med.. 2013 Jan;19(1):57-64

Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression.

Chalmin F, Mignot G, Bruchard M, Chevriaux A, Vegran F, Hichami A, Ladoire S, Derangere V, Vincent J, Masson D, Robson SC, Eberl G, Pallandre JR, Borg C, Ryffel B, Apetoh L, Rebe C, Ghiringhelli F

Immunity. 2012 Mar 23;36(3):362-73

Human ectonucleotidase-expressing CD25(high) Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions.

Thibaudin M, Chaix M, Boidot R, Végran F, Derangère V, Limagne E, Berger H, Ladoire S, Apetoh L, Ghiringhelli F

Oncoimmunology. ;5(1):e1055444